SCHERING-PLOUGH's INTRON A FOR CHRONIC HEPATITIS B RECEIVES ADVISORY COMMITTEE APPROVAL ENDORSEMENT; 42%-54% RESPONSE RATES SEEN IN CLINICAL TRIALS

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".